Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. filed a Form 8-K reporting corporate documentation updates. The filing lists a Certificate of Amendment to the Amended and Restated Certificate of Incorporation and the Second Amended and Restated 2021 Stock Option and Incentive Plan with form award agreements as exhibits. The cover page identifies the company, ticker (BBIO), Nasdaq listing and corporate contact details. The document includes an interactive data file reference and is signed by the company’s Chief Legal Officer and Secretary.